Novartis CEO Vas Narasimhan has joined the board of AI company Anthropic, appointed by the organization's Long-Term Benefit Trust. The move signals a continued focus on responsible AI development, particularly in high-stakes sectors.
Narasimhan, a physician-scientist, leads one of the world's largest pharmaceutical companies. He shares Anthropic's view that AI holds immense potential for improving human life, especially in healthcare and life sciences. This appointment underscores the growing intersection between advanced AI and the medical field.
Daniela Amodei, Anthropic’s President, highlighted Narasimhan's unique experience. "He's overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries," she stated. This background is directly relevant to Anthropic's goal of safely deploying powerful AI systems.
